ATE404217T1 - Therapie mit lipoproteinlipase (lpl) variant - Google Patents

Therapie mit lipoproteinlipase (lpl) variant

Info

Publication number
ATE404217T1
ATE404217T1 AT00943499T AT00943499T ATE404217T1 AT E404217 T1 ATE404217 T1 AT E404217T1 AT 00943499 T AT00943499 T AT 00943499T AT 00943499 T AT00943499 T AT 00943499T AT E404217 T1 ATE404217 T1 AT E404217T1
Authority
AT
Austria
Prior art keywords
lpl
lipoprotein lipase
therapy
variant
conditions
Prior art date
Application number
AT00943499T
Other languages
English (en)
Inventor
Michael Hayden
John Kastelein
Katherine Julia Diane Excoffon
Original Assignee
Univ British Columbia
Amsterdam Molecular Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Amsterdam Molecular Therapeutics Bv filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE404217T1 publication Critical patent/ATE404217T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00943499T 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant ATE404217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24

Publications (1)

Publication Number Publication Date
ATE404217T1 true ATE404217T1 (de) 2008-08-15

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943499T ATE404217T1 (de) 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant

Country Status (12)

Country Link
US (1) US20110201673A1 (de)
EP (1) EP1200117B1 (de)
JP (1) JP5095894B2 (de)
AT (1) ATE404217T1 (de)
AU (1) AU5799200A (de)
CA (1) CA2370081C (de)
CY (1) CY1108511T1 (de)
DE (1) DE60039880D1 (de)
DK (1) DK1200117T3 (de)
ES (1) ES2311464T3 (de)
PT (1) PT1200117E (de)
WO (1) WO2001000220A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044960B1 (de) * 2004-03-02 2013-11-20 Cellectar, Inc. Phospholipid-Analog für die in vivo Diagnose von Krebs
WO2005123117A1 (en) * 2004-06-21 2005-12-29 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of non alcoholic steatotic hepatitis (nash)
CA2622233C (en) 2005-10-20 2015-01-20 Amsterdam Molecular Therapeutics (Amt) B.V. Improved aav vectors produced in insect cells
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
DK3093345T3 (da) 2007-07-26 2019-06-24 Uniqure Ip Bv Baculovirusvektorer omfattende gentagne kodende sekvenser med differentielle foretrukne kodoner
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (de) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Verwendung von lipoprotein-lipase (lpl) in der therapie
ES2799411T3 (es) 2009-06-12 2020-12-17 Cellectar Inc Compuestos alquilfosfolipídicos para el tratamiento de cáncer y obtención de imágenes y detección de células madre cancerosas
US9228174B2 (en) 2010-03-11 2016-01-05 Uniqure Ip B.V. Mutated rep encoding sequences for use in AAV production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
SG10201609345QA (en) 2012-02-07 2017-01-27 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015137802A1 (en) 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
EP3458106A4 (de) * 2016-05-18 2020-03-18 Modernatx, Inc. Polynukleotide zur codierung von lipoproteinlipase zur behandlung von hyperlipidämie
US10286087B2 (en) 2016-12-16 2019-05-14 Uniqure Ip B.V. Immunoadsorption
JP2020526203A (ja) 2017-07-10 2020-08-31 ユニキュアー アイピー ビー．ブイ． ヒトにおけるａａｖ遺伝子療法のための手段及び方法
AU2018303230A1 (en) 2017-07-20 2020-01-30 Uniqure Ip B.V. Improved AAV capsid production in insect cells
WO2019129859A1 (en) 2017-12-29 2019-07-04 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
AU5799200A (en) 2001-01-31
DK1200117T3 (da) 2008-11-17
EP1200117A2 (de) 2002-05-02
CA2370081A1 (en) 2001-01-04
EP1200117B1 (de) 2008-08-13
CA2370081C (en) 2014-06-03
US20110201673A1 (en) 2011-08-18
ES2311464T3 (es) 2009-02-16
JP2003503355A (ja) 2003-01-28
JP5095894B2 (ja) 2012-12-12
WO2001000220A2 (en) 2001-01-04
WO2001000220A3 (en) 2001-07-12
DE60039880D1 (en) 2008-09-25
PT1200117E (pt) 2008-11-26
CY1108511T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CY1108511T1 (el) Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl)
EP1918300A3 (de) Auf Peptiden basierende Immunisierungstherapie zur Behandlung von Atherosklerose
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
DE60235761D1 (de) Isoform des vegfs
BR9707819A (pt) Imunogenos peptidicos
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
DE60039050D1 (de) Antigene meningokokken peptide
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
DE59906362D1 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE69712907T2 (de) Immunogene tlp-zusammensetzung
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
NO964894L (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
DE60231913D1 (de) Mit fettzellendifferenzierung assoziiertes gen und protein
SE9604439D0 (sv) New receptor
WO2001044514A3 (en) Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200117

Country of ref document: EP